Histology diagnosis is essential for the monitoring and management of kidney transplant patients. Nowadays, the accuracy and reproducibility of histology have been criticized when compared with molecular microscopy diagnostic system (MMDx). Our cohort included 95 renal allograft biopsies with both histology and molecular diagnoses. Discrepancies between histology and molecular diagnosis were assessed for each biopsy. Among the 95 kidney allograft biopsies, a total of 6 cases (6%) showed clear (n = 4) or borderline (n = 2) discrepancies between histology and molecular diagnoses. Four out of the six (67%) were cases with pathologically and clinically confirmed active infections that were diagnosed as mild to moderate T-cell-mediated rejection (TCMR) with MMDx. Two cases showed pathological changes that were not sufficient to make a definitive diagnosis of active rejection via histology, while MMDx results showed antibody-mediated rejection (ABMR). In addition, there were six cases with recurrent or de novo glomerular diseases diagnosed only via histology. All other biopsy results were in an agreement. Our results indicate that histology diagnosis of kidney allograft biopsy is superior to molecular diagnosis in the setting of infections and glomerular diseases; however, MMDx can provide helpful information to confirm the diagnosis of active ABMR.

Squamous cell carcinoma (SCC) of cervical origin with metastasis to the brain is rare. Our patient was a 30-year-old Caucasian female with squamous cell carcinoma, initially with unknown primary, with metastases to the brain, kidney, cervix, lung, adrenal glands, vulva, pelvic wall, and scalp. She initially presented to her outpatient gynecologist for a vulvar mass. A biopsy of the vulvar mass was consistent with SCC. The patient continued to have fatigue along with thoracic rib pain. An initial work-up was performed, including imaging which showed diffuse metastatic disease involving the lungs, kidneys and adrenal glands, as well as a pathological compression fracture of the seventh thoracic vertebra with cord compression. Brain magnetic resonance imaging (MRI) showed multiple metastatic lesions and she underwent craniotomy for brain lesion resection. Given the aggressive nature of the patient’s disease and her symptomatic burden, she was started on chemotherapy in the hospital with Carboplatin, Paclitaxel, and Pembrolizumab.

Acute coronary syndrome is caused by a rupture of atherosclerotic plaque with superimposed thrombus formation. Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) occurs when occlusion of the epicardial coronary artery by a thrombus causes partial thickness myocardial ischemia and an ischemic cascade downstream. Cardiac masses are known to produce symptoms predominantly by local obstruction or systemic embolism. Coronary artery tumor embolism causing acute coronary syndrome is a rare presentation of cardiac mass. We report NSTE-ACS as the initial presentation of the left atrial myxoma in a 62-year-old woman. She presented to the emergency department with acute onset severe anginal chest pain, diaphoresis, and dizziness. Her serial electrocardiograms (ECGs) were normal, and serial troponins were elevated, consistent with non-ST-segment elevation acute coronary syndrome. Cardiac catheterization revealed insignificant coronary artery disease, and transthoracic and transesophageal echocardiograms showed a left atrial mass attached to the interatrial septum consistent with myxoma. The patient underwent surgical excision, and histopathology was consistent with myxoma. Her symptoms subsided after surgery. Primary cardiac tumors are very uncommon and can present with myriad symptoms, from tumor embolism, local cardiac effects, to constitutional symptoms. Although embolism to other organs has been reported, left atrial myxoma presenting as an acute coronary syndrome is very uncommon.

Delayed hypersensitivity reactions (DHRs) have been reported in association with COVID-19 vaccines, particularly those that are mRNA-based. Classic DHRs result in induration, erythema, tenderness, and urticaria. However, soft tissue mass is an uncommon complication of a COVID-19 vaccination-associated DHR and is rarely reported in the literature. We present a case of a 49-year-old male who recognized a mildly painful, firm soft tissue mass within the biceps mimicking neoplasm six months after receiving the booster dose of the Moderna vaccine. Non-operative conservative treatment modalities, including heating pads, ice packs, acetaminophen, and ibuprofen, failed to improve the patient’s mass. The mass, which proved histologically to be an inflammatory pseudo-tumor, did not recur after complete excision. While there have been many reported cases of DHRs following COVID-19 vaccinations, we present this case to raise awareness of the development of pseudo-tumors as a possible, yet rare, clinical manifestation of DHRs following vaccination.